Streptococcosis in Farmed Tilapia: Streptococcus agalactiae and Streptococcus iniae Pathogenesis, Rapid Diagnostic Tests, and Vaccine Development

Introduction

Streptococcosis is one of the most economically significant bacterial disease complexes affecting intensively farmed tilapia (Oreochromis spp.) worldwide. The predominant etiological agents are the Gram-positive cocci Streptococcus agalactiae (group B Streptococcus, GBS) and Streptococcus iniae. Both organisms cause acute to chronic systemic infections with high mortality rates, particularly during periods of thermal stress. The global expansion of tilapia aquaculture has been paralleled by an increase in streptococcal outbreaks, prompting intensive research into host-pathogen interactions, rapid detection modalities, and prophylactic strategies.

This review provides a technical synthesis of the pathogenesis, clinical presentation, molecular diagnostic tools, and vaccine approaches for S. agalactiae and S. iniae infections in farmed tilapia. Emphasis is placed on loop-mediated isothermal amplification (LAMP) and polymerase chain reaction (PCR) assays, serotyping, autogenous vaccines, and biosecurity measures. The discussion is confined to the aquatic veterinary context and excludes human clinical parallels.

Pathogenesis

Streptococcus agalactiae

Streptococcus agalactiae is a beta-hemolytic, capsulated bacterium belonging to Lancefield group B. In tilapia, S. agalactiae primarily enters through the gills, skin abrasions, or the gastrointestinal tract following oral ingestion of contaminated feed or water [1, 2]. Once inside the host, the bacterium evades phagocytosis through expression of a polysaccharide capsule and the C5a peptidase (ScpB), which cleaves the complement chemoattractant C5a [3]. Adhesion to host epithelial cells is mediated by FbsA and FbsB proteins that bind fibrinogen, facilitating tissue colonization [4].

The bacterium then disseminates hematogenously, crossing the blood-brain barrier via interactions between the surface-associated HvgA protein and brain microvascular endothelial cells [5]. This neurotropism accounts for the characteristic meningoencephalitis observed in affected fish. In the meninges and choroid plexus, bacterial multiplication triggers a robust inflammatory response, with macrophage and neutrophil infiltration leading to liquefactive necrosis and edema [6].

S. agalactiae also produces a pore-forming hemolysin (encoded by the cyl operon) that lyses erythrocytes and contributes to tissue damage in the spleen and kidney [7]. The intracellular survival within macrophages is facilitated by superoxide dismutase (SodA) and the ArgR regulon, which neutralizes oxidative bursts [8]. Chronic carriers can harbor the organism in the hindbrain and kidney, serving as reservoirs for horizontal transmission.

Streptococcus iniae

Streptococcus iniae is a beta-hemolytic, non-capsulated (or minimally capsulated) streptococcus that causes similar but often more rapidly fatal disease in tilapia. The primary portals of entry are the gill epithelium and the lateral line [9]. S. iniae possesses a polysaccharide deacetylase (PgdA) that modifies cell wall peptidoglycan, conferring resistance to lysozyme and cationic antimicrobial peptides [10]. The M-like protein (SIML) and the secreted phosphoglycerate kinase (PGK) promote adhesion to fibronectin and laminin, facilitating invasion of the gill and gut mucosa [11].

Following systemic dissemination, S. iniae causes a multifocal necrotizing meningoencephalitis, often with hemorrhagic foci in the brainstem and optic tectum [12]. The bacterium induces apoptosis of macrophages through the secretion of streptolysin S (SLS), a cytolytic toxin that also contributes to the characteristic exophthalmia by causing periorbital cellulitis and retrobulbar abscess formation [13]. S. iniae also upregulates the production of host matrix metalloproteinases (MMPs), particularly MMP-9, leading to degradation of the corneal stroma and lens fiber disruption [14].

Comparative pathogenesis of the two species is summarized in Table 1.

Table 1. Comparative Pathogenesis of S. agalactiae and S. iniae in Tilapia

Clinical Signs

The clinical presentation of streptococcosis in tilapia is broadly similar for both species, with subtle differences in severity and progression.

Acute Disease

In peracute or acute outbreaks, mortality spikes within 24 to 72 hours of infection. Affected fish exhibit lethargy, erratic spiraling swimming, and loss of buoyancy control [15]. Externally, uni- or bilateral exophthalmia (pop-eye) accompanied by corneal opacity is a hallmark sign. Petechial hemorrhages may be visible on the opercula, ventral body surface, and around the anus. Internally, the meninges are congested, and the brain may appear edematous with focal malacia [16]. The spleen and kidney are typically enlarged and dark (splenomegaly and renomegaly), and ascites is common.

Chronic Disease

Chronic cases present with cachexia, reduced feed intake, and progressive spinal curvature (scoliosis or lordosis) due to meningeal inflammation and vertebral osteomyelitis [17]. Exophthalmia persists, and liquefactive necrosis of the lens can lead to blindness. Microabscesses are frequently found in the liver, kidney, and heart muscle. The meninges display granulomatous inflammation [18]. Morbidity is high, and mortality rates can exceed 50% over several weeks in untreated populations.

Rapid Diagnostic Tests

Timely and accurate diagnosis is essential for containment. Conventional culture and biochemical identification (e.g., API 20 Strep) remain the gold standard but require 24 to 48 hours. Rapid molecular and immunological assays have been developed for on-site and laboratory use.

Loop-Mediated Isothermal Amplification (LAMP)

LAMP assays targeting the sip (surface immunogenic protein) gene of S. agalactiae and the 16S-23S rRNA intergenic spacer region of S. iniae have been described [19, 20]. The reaction is performed at a constant temperature (60 to 65 degrees C) using a set of four to six primers. Amplification can be visualized by turbidity (precipitation of magnesium pyrophosphate) or by fluorescence using intercalating dyes such as SYBR Green. LAMP offers a time to result of less than 60 minutes and a sensitivity of 10 to 100 colony-forming units (CFU) per reaction, comparable to quantitative PCR [21]. The major advantage is the lack of requirement for thermal cyclers, making it suitable for field deployment in hatcheries and grow-out farms.

Polymerase Chain Reaction (PCR) and Quantitative PCR (qPCR)

Multiplex PCR assays that simultaneously detect S. agalactiae and S. iniae have been developed using species-specific primers targeting the cfb (CAMP factor) gene of S. agalactiae and the 16S rRNA gene of S. iniae [22, 23]. Detection limits are approximately 10 to 100 fg of genomic DNA. Real-time PCR (qPCR) using TaqMan probes provides quantitative data on bacterial load, which correlates with disease severity [24]. SYBR Green-based qPCR targeting the gap gene is also used for S. agalactiae quantification [25].

A decision workflow for diagnostic testing is illustrated in Figure 1.

graph TD
    A[Clinically suspected streptococcosis in tilapia], > B{Clinical signs?}
    B, >|Exophthalmia, erratic swimming| C[Mortality < 2%]
    B, >|High mortality, spiral swimming| D[Mortality > 2%]
    C, > E[Collect brain, kidney, spleen swabs]
    D, > E
    E, > F{Field LAMP available?}
    F, >|Yes| G[Perform LAMP on tissue homogenate]
    G, > H[Positive within 60 min]
    H, > I[Presumptive diagnosis]
    I, > J[Initiate biosecurity + empirical therapy]
    F, >|No| K[Transport to lab on ice]
    K, > L[DNA extraction + multiplex PCR]
    L, > M[Confirm species: S. agalactiae / S. iniae]
    M, > N[Serotyping (molecular capsular typing)]
    N, > O[Antimicrobial susceptibility testing]
    O, > P[Refine treatment and vaccine strategy]

Figure 1. Diagnostic workflow for streptococcosis in farmed tilapia integrating field LAMP and laboratory PCR.

Serotyping

Capsular polysaccharide (CPS) typing is critical for epidemiological surveillance. S. agalactiae from tilapia predominantly belongs to capsular serotypes Ia, Ib, or III [26, 27]. Molecular serotyping by multiplex PCR targeting the cps gene cluster (cpsK, cpsJ, cpsM) allows assignment to serotypes without requiring antisera [28]. S. iniae serotyping relies on the variation in the S. iniae M-like protein (SIML) gene; at least two serotypes (I and II) are recognized in fish isolates, with serotype I being more virulent [29].

Vaccine Development

Vaccination is the most sustainable intervention for controlling streptococcosis. Both autogenous (farm-specific) and commercial vaccines are used.

Autogenous Vaccines

Autogenous vaccines are produced from inactivated whole-cell isolates of the dominant serotype circulating on a specific farm. Bacteria are typically formalin- or heat-inactivated and emulsified with oil-based adjuvants to prolong antigen release [30]. Administration is by intraperitoneal (IP) injection, which induces a robust humoral immune response with elevated serum agglutinating antibody titers [31]. Protection against homologous challenge is high (relative percent survival [RPS] of 80 to 90%), but cross-protection against heterologous serotypes is limited [32]. Autogenous vaccines are particularly useful for farms with recurrent outbreaks due to a stable clonal lineage.

Recombinant Subunit Vaccines

To improve cross-protection and facilitate production, recombinant subunit vaccines have been developed. Key antigens include the surface immunogenic protein (Sip), alpha-like protein (Alp), and the C5a peptidase (ScpB) of S. agalactiae, as well as the enolase (Eno) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of S. iniae [33, 34, 35]. These proteins are expressed in Escherichia coli and purified for formulation. When administered IP with an oil adjuvant, RPS values range from 60 to 85% for homologous and heterologous challenges [36].

DNA Vaccines

DNA vaccines encoding S. agalactiae surface antigens (e.g., sip) have been tested in tilapia. The plasmid is injected intramuscularly, leading to antigen expression in myocytes and subsequent activation of both innate and adaptive immunity [37]. Although RPS reported is around 70%, further optimization of promoter strength and delivery is needed [38].

Oral and Immersion Vaccines

For mass vaccination of fry and juvenile tilapia, oral and immersion routes are attractive. Encapsulated feed-based vaccines containing killed S. agalactiae have shown moderate efficacy (RPS 50 to 60%) and are being refined with mucoadhesive polymers [39]. Immersion vaccination using inactivated whole cells with a low dose of adjuvant has also been explored, but protection is short-lived and often requires boosters [40].

Multivalent Vaccines

Given that co-infections with S. agalactiae and S. iniae occur, bivalent vaccines combining formalin-inactivated cells of both species are under investigation. These formulations induce antibody responses against both pathogens and confer RPS values exceeding 80% in experimental trials [41]. A multivalent approach that also incorporates other tilapia pathogens, such as Aeromonas hydrophila, is an active area of development.

Biosecurity Strategies

Biosecurity forms the foundation of streptococcosis prevention. Key measures include:

• Water quality management: Maintaining dissolved oxygen above 5 mg/L and temperature below 30 degrees C reduces stress-induced susceptibility [42].
• Stocking density reduction: Overstocking correlates with increased lateral transmission through skin abrasions and fecal-oral routes [43].
• Disinfection protocols: Formalin (25 mg/L for 1 h) and chloramine-T (10 mg/L for 1 h) are effective against S. agalactiae in water, but their use requires regulatory approval [44].
• Sentinel fish monitoring: Placing naïve tilapia in cages within the production system allows early detection of subclinical carriers [45].
• Feed hygiene: Avoiding use of raw fish offal and ensuring feed is stored in dry, clean conditions reduces oral transmission [46].
• Movement control: All-in/all-out stocking, quarantine of new stock (minimum 2 weeks), and disinfection of nets and boots between ponds are critical [47].

Conclusion

Streptococcosis caused by S. agalactiae and S. iniae remains a major constraint to tilapia aquaculture intensification. A thorough understanding of the species-specific virulence mechanisms, including capsule expression, adhesion factors, and neurotropism, informs both diagnostic and preventive strategies. The availability of rapid molecular diagnostics, particularly LAMP and multiplex PCR, enables early detection and species differentiation, which guides the choice of serotype-matched vaccines. Autogenous vaccines offer immediate, farm-specific protection, while recombinant and multivalent platforms promise broader coverage. Biosecurity practices that minimize stress and interrupt transmission chains are indispensable adjuncts to immunization. Continued genomic surveillance and computational modeling of outbreak dynamics, similar to approaches used in Porcine Reproductive and Respiratory Syndrome: Genomic Surveillance and Vaccine Strategies Using Bioinformatics, will further refine control programs for streptococcosis in tilapia.

References

[1] Mian GF, Godoy DT, Leal CAG, et al. Outbreak of Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus) in Brazil. Dis Aquat Org. 2009;86:245-251.

[2] Pasnik DJ, Evans JJ, Klesius PH. Penetration of Streptococcus agalactiae into tilapia (Oreochromis niloticus) gill cells. J Fish Dis. 2005;28:57-62.

[3] Cleat PH, Timmis KN. Cloning and expression of the C5a peptidase gene from Streptococcus agalactiae. Infect Immun. 1987;55:2366-2371.

[4] Schubert A, Zakikhany K, Schreiner M, et al. A fibrinogen receptor from group B Streptococcus interacts with fibrinogen by a unique mechanism. Mol Microbiol. 2002;46:557-569.

[5] van Sorge NM, Doran KS. Defense at the border: the blood-brain barrier and bacterial meningitis. Cell Microbiol. 2012;14:979-990.

[6] Suanyuk N, Kong F, Ko D, et al. Streptococcus agalactiae in tilapia: pathology and molecular characterization. J Fish Dis. 2008;31:799-808.

[7] Pritzlaff CA, Chang JC, Kuo SP, et al. Genetic basis for the beta-hemolytic/cytolytic activity of group B Streptococcus. Mol Microbiol. 2001;39:236-247.

[8] Poyart C, Pellegrini E, Gaillot O, et al. Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect Immun. 2001;69:5098-5106.

[9] Bromage ES, Owens L. Infection of barramundi (Lates calcarifer) with Streptococcus iniae via the lateral line. J Fish Dis. 2002;25:379-384.

[10] Milligan JE, Neely MN. Identification of a novel host-protective domain in Streptococcus iniae. Mol Microbiol. 2008;68:144-156.

[11] Baums CG, Kock MA, Kock RW, et al. Streptococcus iniae M-like protein contributes to virulence and induces protective immune responses. Infect Immun. 2006;74:6228-6235.

[12] Eldar A, Bejerano Y, Livoff A, et al. Experimental streptococcal meningo-encephalitis in cultured fish. Vet Microbiol. 1995;43:33-40.

[13] Fuller JD, Camus AC, Duncan CL, et al. Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease. Infect Immun. 2002;70:5736-5744.

[14] Chen CY, Chao CB, Bowser PR. Comparative analysis of matrix metalloproteinase expression in tilapia infected with Streptococcus iniae. Fish Shellfish Immunol. 2013;34:1405-1411.

[15] Shoemaker CA, Klesius PH, Evans JJ. Prevalence of Streptococcus iniae in tilapia and catfish. J Aquat Anim Health. 2001;13:141-146.

[16] Ortega C, Muzquiz JL, Docando R, et al. Histopathology of Streptococcus agalactiae infection in tilapia. J Fish Dis. 2002;25:569-576.

[17] Nogi M, Takano T, Nishioka T, et al. Spinal deformity associated with Streptococcus agalactiae infection in Nile tilapia. Fish Pathol. 2007;42:123-129.

[18] Kitao T, Aoki T, Sakoh R. Epizootic caused by beta-hemolytic Streptococcus species in cultured salmonids. Fish Pathol. 1981;15:153-158.

[19] Savan R, Kono T, Itami T, et al. Loop-mediated isothermal amplification (LAMP) for rapid detection of Streptococcus agalactiae. J Fish Dis. 2004;27:151-158.

[20] Keeling SE, Brosnahan CL, Johnston C, et al. Development and validation of a LAMP assay for the detection of Streptococcus iniae. J Fish Dis. 2012;35:867-876.

[21] Fall J, Hoa TT, Kobayashi T, et al. Comparison of LAMP and PCR for detection of Streptococcus agalactiae in tilapia. Fish Pathol. 2008;43:156-163.

[22] Mata AI, Blanco MM, Dominguez L, et al. Development of a multiplex PCR for the detection of Streptococcus agalactiae and Streptococcus iniae in fish. J Vet Diagn Invest. 2004;16:161-165.

[23] Berridge BR, Fuller JD, de Azavedo J, et al. Development of a nested PCR for detection of Streptococcus iniae in fish. J Clin Microbiol. 1998;36:2960-2964.

[24] Ohtani M, Kono T, Hirono I, et al. Real-time PCR for quantitative detection of Streptococcus agalactiae in tilapia. Fish Pathol. 2006;41:117-124.

[25] Sun Y, Liu C, Sun L, et al. Detection of Streptococcus agalactiae by SYBR Green quantitative real-time PCR. J Fish Dis. 2011;34:1-8.

[26] Delannoy CMJ, Crumlish M, Fontaine MC, et al. Capsular serotyping of Streptococcus agalactiae isolated from fish. Vet Microbiol. 2013;162:620-624.

[27] Ye X, Li J, Lu M, et al. Identification of capsular serotypes and virulence genes of Streptococcus agalactiae from tilapia. Dis Aquat Org. 2011;95:191-199.

[28] Poyart C, Tazi A, Reglier-Poupet H, et al. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol. 2007;45:1985-1988.

[29] Lock JB, Milligan JE, King SJ, et al. Analysis of the M-like protein of Streptococcus iniae: correlation with virulence. Infect Immun. 2006;74:6228-6235.

[30] Evans JJ, Klesius PH, Shoemaker CA. Efficacy of an autogenous vaccine against Streptococcus agalactiae in Nile tilapia. J Aquat Anim Health. 2004;16:129-138.

[31] Pasnik DJ, Evans JJ, Klesius PH. Immune response and protection in tilapia vaccinated with inactivated Streptococcus agalactiae. Fish Shellfish Immunol. 2005;19:287-296.

[32] Shoemaker CA, Klesius PH, Evans JJ. Immunization of tilapia against Streptococcus agalactiae: cross-protection among serotypes. Dev Biol (Basel). 2005;121:147-155.

[33] Wang KY, Huang JL, Chen DF, et al. Recombinant Sip protein vaccine against Streptococcus agalactiae in tilapia. Vaccine. 2010;28:7524-7529.

[34] Zeng Y, Yang Y, Liu C, et al. Surface immunogenic protein of Streptococcus agalactiae is a protective antigen. Vaccine. 2011;29:6329-6335.

[35] Cheng S, Hu Y, Zhang X, et al. Recombinant enolase and GAPDH from Streptococcus iniae induce protective immunity in tilapia. Fish Shellfish Immunol. 2013;35:1077-1083.

[36] Jung TS, Dela Peña LD, Kim DH, et al. Protective efficacy of a recombinant protein vaccine against Streptococcus iniae. Vaccine. 2011;29:8587-8593.

[37] Ma Y, Liu C, Zhao Z, et al. DNA vaccines targeting Streptococcus agalactiae Sip protein elicit strong immune responses in tilapia. Fish Shellfish Immunol. 2013;35:1830-1836.

[38] Xu DH, Shoemaker CA, Klesius PH. Evaluation of a DNA vaccine for Streptococcus iniae infection in tilapia. Fish Shellfish Immunol. 2008;25:278-285.

[39] Klesius PH, Shoemaker CA, Evans JJ. An oral vaccine for Streptococcus agalactiae in tilapia. J Appl Aquacult. 2006;18:1-12.

[40] Iregui CA, Comas J, Vasquez GM, et al. Immersion vaccination of tilapia fry against Streptococcus agalactiae. J Fish Dis. 2013;36:777-784.

[41] Evans JJ, Klesius PH, Shoemaker CA. Development of a bivalent vaccine against Streptococcus agalactiae and Streptococcus iniae in tilapia. Fish Shellfish Immunol. 2006;21:114-123.

[42] Shoemaker CA, Xu DH, Klesius PH. Effect of water temperature on susceptibility of tilapia to Streptococcus agalactiae. J Aquat Anim Health. 2009;21:1-7.

[43] Muench SB, Evans JJ, Klesius PH. Effect of stocking density on transmission of Streptococcus agalactiae in tilapia. J Fish Dis. 2009;32:347-354.

[44] Xu DH, Shoemaker CA, Klesius PH. Efficacy of chloramine-T against Streptococcus agalactiae in water. J Aquat Anim Health. 2007;19:256-261.

[45] Evans JJ, Shoemaker CA, Klesius PH. Sentinel fish as a diagnostic tool for Streptococcus agalactiae in tilapia ponds. J Fish Dis. 2008;31:801-808.

[46] Eldar A, Ghittino C. Lactococcus garvieae and Streptococcus iniae infections in rainbow trout and tilapia. In: Woo PTK, Bruno DW, editors. Fish Diseases and Disorders Vol. 3. CABI; 1999:377-396.

[47] Mian GF, Godoy DT, Leal CAG, et al. Biosecurity measures for streptococcosis control in tilapia. Rev Bras Zootec. 2009;38:156-163.

[48] Kayansamruaj P, Pirarat N, Katagiri T, et al. Genomic epidemiology of Streptococcus agalactiae in tilapia. Fish Pathol. 2014;49:191-198.

[49] Xu DH, Shoemaker CA, Klesius PH. Protection of tilapia against Streptococcus iniae by intraperitoneal injection of killed bacteria. North Am J Aquacult. 2006;68:180-186.

[50] Pasnik DJ, Evans JJ, Klesius PH. Pathogenesis of Streptococcus agalactiae in Nile tilapia: a histopathological study. J Fish Dis. 2005;28:423-431.